You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2025

Drug Price Trends for NDC 15370-0180


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 15370-0180

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Pharmaceutical Drugs: A Comprehensive Overview

Last updated: January 1, 2025

Introduction

The pharmaceutical industry is a complex and dynamic sector, influenced by a myriad of factors including technological advancements, regulatory changes, and economic trends. This article will delve into the market analysis and price projections for pharmaceutical drugs, using the example of a specific drug identified by its National Drug Code (NDC) to illustrate broader industry trends.

Understanding the National Drug Code (NDC)

The NDC is a unique, three-segment number that identifies drug products. For example, the NDC 15370-170 corresponds to RELAFEN DS, a nonsteroidal anti-inflammatory drug (NSAID) with the active ingredient Nabumetone[1][5].

Current Market Trends in Pharmaceuticals

The pharmaceutical industry is experiencing significant growth and transformation. Here are some key trends:

Digital Transformation and AI

AI is revolutionizing drug development by accelerating the identification of potential compounds and predicting the effectiveness and safety of drugs. This has reduced the time and cost associated with bringing new drugs to market from 10 years and $2.6 billion to just 4 years and significantly lower costs[3].

Gene Editing and Personalized Medicine

Technologies like CRISPR are transitioning from lab theories to real treatments, enabling the cure of diseases previously thought to be permanent. Personalized medicine, tailored to individual genetic codes, is becoming more prevalent[3].

Drug Price Inflation

Vizient projects a 3.81% overall drug price inflation rate for 2025, driven by factors such as the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[2].

Global Pricing Disparities

Drug prices vary significantly across different regions. In the U.S., the average price per unit is 5.5 times higher than in the OECD (excluding the U.S.) and 7.7 times higher than in the rest of the world. This disparity is partly due to a drug mix that skews towards more expensive compounds in the U.S.[4].

Market Segmentation and Sales Trends

  • Retail vs. Non-Retail Markets: In the U.S., sales revenues grew similarly in both retail and non-retail markets, whereas in other regions, retail markets contracted while non-retail markets grew[4].
  • Small Molecule Drugs vs. Biologic Products: U.S. sales revenues for small molecule drugs grew by 4%, while biologic products saw a significant 61% growth. In contrast, other regions experienced contractions in small molecule drug sales[4].

Regulatory and Compliance Issues

The FDA's National Drug Code Database ensures that all listed drug products comply with regulatory provisions. Non-compliance can result in a product being excluded from the directory[5].

Price Projections for Specific Drugs

While specific price projections for NDC 15370-170 (RELAFEN DS) are not available, we can infer trends based on broader industry data:

Impact of Inflation

Given the projected 3.81% drug price inflation rate for 2025, it is likely that the price of RELAFEN DS will increase accordingly. This inflation is driven by broader market trends rather than specific changes to this drug[2].

Technological Advancements

The integration of AI and other digital tools in drug development could lead to more efficient production processes, potentially stabilizing or reducing prices in the long term. However, the immediate impact on existing drugs like RELAFEN DS may be minimal[3].

Global Pricing Trends

The significant price disparities between the U.S. and other regions suggest that RELAFEN DS, like other drugs, will continue to be priced higher in the U.S. compared to other markets[4].

Key Takeaways

  • Technological Advancements: AI and gene editing are transforming the pharmaceutical industry, speeding up drug development and potentially reducing costs.
  • Price Inflation: A projected 3.81% drug price inflation rate for 2025 indicates that prices for drugs like RELAFEN DS are likely to increase.
  • Global Pricing Disparities: Drugs are significantly more expensive in the U.S. compared to other regions.
  • Regulatory Compliance: Ensuring compliance with FDA regulations is crucial for maintaining market presence.

FAQs

Q: What is the National Drug Code (NDC) and how is it used? A: The NDC is a unique three-segment number that identifies drug products, including the labeler, product, and package size. It is used to track and regulate drug products[5].

Q: How is AI impacting the pharmaceutical industry? A: AI is accelerating drug development by analyzing vast datasets, predicting drug success rates, and enhancing the safety and effectiveness of drugs[3].

Q: Why are drug prices higher in the U.S. compared to other regions? A: Drug prices in the U.S. are higher due to a drug mix that skews towards more expensive compounds and higher overall prices for the same drugs compared to other regions[4].

Q: What are the projected price trends for pharmaceutical drugs in 2025? A: Vizient projects a 3.81% overall drug price inflation rate for 2025, driven by expanding indications of previously approved medications and the introduction of high-cost therapies[2].

Q: How do technological advancements affect the pricing of existing drugs? A: While technological advancements like AI can lead to more efficient production processes, their immediate impact on the pricing of existing drugs may be minimal. However, they could stabilize or reduce prices in the long term[3].

Sources

  1. FDA.report: NDC 15370-170 Oral Tablet RELAFEN DS Drug Codes.
  2. Vizient Inc.: Vizient projects drug price inflation at 3.81%.
  3. Laboratorios Rubio: The Future of Pharma: 2025's Key Trends To Know.
  4. ASPE: ISSUE BRIEF - International Market Size and Prices.
  5. FDA: National Drug Code Database Background Information.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.